Covered recipient · General Payments record
ALLISON C GAPINSKI
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2022–2024
$893.59
- Reported across 39 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $255.73 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $73.04 | 4 |
| Abbott Laboratories | $39.77 | 2 |
| Sumitomo Pharma America, Inc. | $21.17 | 1 |
| Novo Nordisk AS | $18.42 | 1 |
| iRhythm Technologies, Inc. | $17.21 | 1 |
| Merck Sharp & Dohme Corporation | $15.47 | 1 |
| Acerta Pharma LLC | $14.79 | 1 |
| PFIZER INC. | $14.30 | 1 |
| ABBVIE INC. | $14.05 | 1 |
| SHIELD THERAPEUTICS INC | $13.97 | 1 |
| GlaxoSmithKline, LLC. | $13.54 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $23.92 | 02/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125285040 | CMS |
| Abbott Laboratories | $15.85 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125285042 | CMS |
| ABBVIE INC. | $14.05 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107147222 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.79 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105887017 | CMS |
| GlaxoSmithKline, LLC. | $13.54 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116691043 | CMS |
| iRhythm Technologies, Inc. | $17.21 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154047241 | CMS |
| Lilly USA, LLC | $22.53 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135526857 | CMS |
| Lilly USA, LLC | $19.88 | 03/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135461178 | CMS |
| Lilly USA, LLC | $13.64 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135526859 | CMS |
| Lilly USA, LLC | $16.99 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135520867 | CMS |
| Merck Sharp & Dohme LLC | $15.47 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141965751 | CMS |
| Novo Nordisk Inc | $18.42 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100542370 | CMS |
| PFIZER INC. | $14.30 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131123626 | CMS |
| SHIELD THERAPEUTICS INC | $13.97 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150121181 | CMS |
| Sumitomo Pharma America, Inc. | $21.17 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148961444 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.